Sulfadoxine-pyrimethamine

Access

-

Approved

Wiwal®

Universal Corporation

Chemoprevention

Intermittent preventative treatment (TPP-1)

Product vision	Intermittent preventive treatment during pregnancy (IPTp) Intermittent preventive treatment of infants (IPTi)
Dosing	3 tablets of 500 mg sulfadoxine - 25 mg pyrimethamine (SP), to be given monthly at the beginning of the 2nd trimester of pregnancy until delivery
Efficacy	WHO affirmed the effectiveness of IPTp using SP (IPTp-SP), including in areas with SP resistance Full course of IPTp-SP decreases incidence of low birthweight babies by 29%, severe maternal anaemia by 38%, and neonatal mortality by 31%.
Key features	One of the few health interventions showing reductions in neonatal mortality Adapted SP packaging to ensure correct use and to improve perception and uptake
Challenges	Delivery of IPTp requires a functioning antenatal care platform and access to quality-assured SP Improving quality perceptions about SP and expanding access through community health worker channels can increase IPTp coverage
Status	WHO Prequalification in August 2022. Approved in Kenya with further registration submissions (Cameroon & Ghana) 250 mg Sulfadoxine-12.5 mg pyrimethamine dispersible tablets for use in infants (IPTi) approved by Global Fund Expert Review Panel in 2022
Next milestone	Ongoing country registrations in Uganda, Rwanda, Zambia, Malawi, Tanzania
Project Director	Pierre Hugo